MedTrace Logo

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers

NCT05007275 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-09-06

No results posted yet for this study

Summary

This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in volunteers previously vaccinated by intramuscular COVID-19 vaccination. Using standardised methods, we will measure immune responses in the blood, nose and lower airway and compare with data from ongoing clinical trials of intramuscular vaccination. Thus, we will show the effect of the delivery method and provide the critical information required to begin further clinical trials to show the efficacy of this needle-free vaccination strategy for booster vaccination.

Conditions

Interventions

BIOLOGICAL

1x10^9 vp AZD1222

A single dose of 1x 10\^9 vp AZD1222

BIOLOGICAL

5x10^9 vp AZD1222

A single dose of 5x 10\^9 vp AZD1222

BIOLOGICAL

1x10^10 vp AZD1222

A single dose of 1x10\^10 vp AZD1222

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Chris Chiu, PhD · Imperial College London

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007275 on ClinicalTrials.gov